17 research outputs found
EP-1042: Risk-factors in pT1-2N0M0 squamous cancers of the oral cavity and the role of adjuvant radiotherapy
The Maximum Limit of Rotational Energy Transfer in Molecular Collisions and the Hard Ellipsoid Potential Model
The maximum limit of rotational energy transfer was investigated over a wide range of collision energy, reduced mass of the system, potential functions, and potential parameters for the N-Ne system. The classical limit of maximum rotational energy transfer, (ΔE), was reviewed for a hard ellipsoid potential model. It was found that (ΔE) predicted by the hard ellipsoid model is comparable to a well-known parameter |ΔE|* given by the power-gap law. The numerical equivalence of |ΔE|* with (ΔE)_max suggests that the value of ΔE) given by hard ellipsoid potential model can be used as one parameter |ΔE|* of the power-gap law
P26 Lung Cancer in Adolescent & Young Adults: Single Center Experience from Eastern India
Acute promyelocytic leukemia: An experience from a tertiary care centre in north India
Background: There are very limited data reported about acute
promyelocytic leukemia (APL) from developing countries. We reviewed the
clinical course and treatment outcome of APL patients treated at our
center. Materials and Methods: Between January 1997 and December 2007,
33 patients with APL received induction therapy using ATRA +
daunorubicin (n = 26), As = 26), As2O3 (n = 4) or daunorubicin +
cytosar ( n = 3). Results: Median age was 30 years with a male to
female ratio of 1.68. Twenty seven patients (82%) achieved CR.
Complications during induction therapy were febrile neutropenia (33%),
ATRA syndrome (30%), bleeding (58%), and diarrhea in (6%) patients.
During induction and follow up, 8 (24.24%) patients died, 6 (18.18%)
during induction, 1 (3%) during maintenance, and 1 (3%) after relapse.
Median OS is 128 months while median EFS is 61 months. Four patients
relapsed at a median time of 61 months. At the time of censoring, 25
patients were alive at a median follow up of 13 months (range 0.6 -127
months); 21 in CR1, 3 in CR2, 1 in CR3. Comparisons among the risk
groups (CR and relapse rate and survival statistics) were not
statistically significant. Conclusions: APL is a highly curable
malignancy. Our results confirm the findings of the published
literature from larger cooperative studies from the West. We may
further improve outcome with quicker diagnosis and more efficient
supportive care system
Acute promyelocytic leukemia: an experience from a tertiary care centre in North India
Background: There are very limited data reported about acute promyelocytic leukemia (APL) from developing countries. We reviewed the clinical course and treatment outcome of APL patients treated at our center. Materials and Methods: Between January 1997 and December 2007, 33 patients with APL received induction therapy using ATRA + daunorubicin (n = 26), As = 26), As2O3 (n = 4) or daunorubicin + cytosar ( n = 3). Results: Median age was 30 years with a male to female ratio of 1.68. Twenty seven patients (82%) achieved CR. Complications during induction therapy were febrile neutropenia (33%), ATRA syndrome (30%), bleeding (58%), and diarrhea in (6%) patients. During induction and follow up, 8 (24.24%) patients died, 6 (18.18%) during induction, 1 (3%) during maintenance, and 1 (3%) after relapse. Median OS is 128 months while median EFS is 61 months. Four patients relapsed at a median time of 61 months. At the time of censoring, 25 patients were alive at a median follow up of 13 months (range 0.6 -127 months); 21 in CR1, 3 in CR2, 1 in CR3. Comparisons among the risk groups (CR and relapse rate and survival statistics) were not statistically significant. Conclusions: APL is a highly curable malignancy. Our results confirm the findings of the published literature from larger cooperative studies from the West. We may further improve outcome with quicker diagnosis and more efficient supportive care system
Multiple myeloma: Autologous stem cell transplantation versus conventional chemotherapy—A retrospective age and stage matched analysis
Acute promyelocytic leukemia: An experience from a tertiary care centre in north India
Background: There are very limited data reported about acute
promyelocytic leukemia (APL) from developing countries. We reviewed the
clinical course and treatment outcome of APL patients treated at our
center. Materials and Methods: Between January 1997 and December 2007,
33 patients with APL received induction therapy using ATRA +
daunorubicin (n = 26), As = 26), As2O3 (n = 4) or daunorubicin +
cytosar ( n = 3). Results: Median age was 30 years with a male to
female ratio of 1.68. Twenty seven patients (82%) achieved CR.
Complications during induction therapy were febrile neutropenia (33%),
ATRA syndrome (30%), bleeding (58%), and diarrhea in (6%) patients.
During induction and follow up, 8 (24.24%) patients died, 6 (18.18%)
during induction, 1 (3%) during maintenance, and 1 (3%) after relapse.
Median OS is 128 months while median EFS is 61 months. Four patients
relapsed at a median time of 61 months. At the time of censoring, 25
patients were alive at a median follow up of 13 months (range 0.6 -127
months); 21 in CR1, 3 in CR2, 1 in CR3. Comparisons among the risk
groups (CR and relapse rate and survival statistics) were not
statistically significant. Conclusions: APL is a highly curable
malignancy. Our results confirm the findings of the published
literature from larger cooperative studies from the West. We may
further improve outcome with quicker diagnosis and more efficient
supportive care system